Tromsø, Norway, 20th May 2020 – Biotec Pharmacon (OSE: Biotec) announces that its subsidiary, ArcticZymes AS, has been granted up to NOK 1.65 million by Innovation Norway for a project to increase the manufacturing scale of its SAN-HQ enzyme ArcticZymes’ Salt Active Nuclease High Quality (SAN-HQ) enzyme offers gene therapy and vaccine customers a more cost effective and technically superior …